Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
評估Novo Nordisk: 從8位金融分析師的見解中獲得洞察力
Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Novo Nordisk (NYSE:NVO) in the last three months.
在過去三個月中，有8位分析師公佈了諾和諾德（紐約證券交易所代碼：NVO）的評級，提供了從看漲到看跌的不同視角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $160.38, a high estimate of $163.00, and a low estimate of $160.00. This current average represents a 0.77% decrease from the previous average price target of $161.62.
分析師通過對12個月目標股價的評估提供了更深入的見解，顯示平均目標價爲160.38美元，最高估計爲163.00美元，低估值爲160.00美元。目前的平均價格比之前的平均目標價161.62美元下降了0.77％。
Investigating Analyst Ratings: An Elaborate Study
調查分析師評級：一項詳盡的研究
The perception of Novo Nordisk by...
金融專家通過...
登入免費觀看全文
登入/註冊